Our commitment to HIV treatments and prevention through the years

We continue to work at the forefront of the fight against HIV

March 15, 2021

Share this article


HIV history - Merck scientist in the lab

HIV (human immunodeficiency virus) continues to be a major public health threat. The virus can lead to AIDS.

Since 1985, our company has been engaged in research and development (R&D) efforts in the prevention and treatment of HIV. Over the years, our scientists have made significant discoveries that changed the way HIV is treated. Here are some historical moments highlighting this effort:

  • Merck scientist studies the structure of the HIV-1 protease
  • Members of the HIV protease research team
  • Linda Distlerath
  • 5 Merck HIV scientists
  • AIDS quilts
  • Daria Hazuda
  • In 1982, the U.S. Centers for Disease Control and Prevention first used the term “AIDS,” or acquired immune deficiency syndrome, to describe the clinical syndrome caused by the human immunodeficiency virus (HIV).
  • In the mid-1980s, Merck launched its HIV research program in response to what it perceived as a potential epidemic. Our scientists were among the first to discover and develop medicines for the treatment of HIV.
  • We were the first to publish the crystal structure of HIV protease, which is an enzyme which is essential for virus infectivity.
  • In 1992, Merck joined other pharmaceutical companies to create the Inter-Company Collaboration for AIDS Drug Development to research HIV treatments. By 1993, we were undertaking the biggest research program in our history, deploying more scientists to investigate AIDS than any other disease and testing tens of thousands of compounds.
  • The HIV/AIDS community continued to speak out for action. In 1995, Linda Distlerath, former executive director, Public Policy and Merck Research Laboratories Public Affairs, spent time reading letters sent from thousands of AIDS patients and activists urging Merck to produce a treatment for the disease quickly.
  • After years of study and development, Merck developed one of the first protease inhibitors. In 1995, prior to FDA approval, in conjunction with the U.S. Food and Drug Administration, patients and HIV advocacy groups, Merck offered a program that made its new HIV treatment available at no cost to selective patients before it was commercially available.
  • In 1996, the HIV treatment received FDA approval in a record-setting 42 days. It was an important early achievement in making HIV a survivable infection.
  • In 2012, The NAMES Project Foundation – with support from Merck – launched Call My Name national tour to bring attention to the distressing trajectory of the HIV epidemic in the Black communities in the U.S. The tour included creating new panels for the AIDS memorial quilt and educational workshops in 10 high-prevalence cities.
  • Daria Hazuda, VP, infectious disease discovery and chief scientific officer, Merck Exploratory Science Center has led the team working to identify new ways to attack and treat HIV.
  • In 2021, we entered into an agreement with Gilead to work together in the global HIV community in the fight against HIV.